AHA26: Orforglipron outpaces oral semaglutide on predicted cardiovascular risk

GlobalData expects Eli Lilly to pair this CV risk data with orforglipron’s dosing convenience to differentiate it from oral semaglutide.

GlobalData Healthcare November 11, 2026

In ACHIEVE-4, orforglipron lowered the risk of heart attack, stroke, or CV death by 16% compared with insulin glargine in patients at increased CV risk, and the ongoing ATTAIN-Outcomes trial will provide the definitive test. Image credit: Shutterstock/[PeopleImages]

Unlock FREE Access to Premium Content

Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.

With a free Clinical Trials Arena profile, you can:

Access exclusive analyst commentary and expert insights
View premium forecasts and data-driven clinical trial intelligence
Stay up to date with clinical trial news, regulatory updates, and industry trends
Receive alerts when new premium content is published